Various newer treatments have been developed for relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL). The Murano study first presented results in 2017 and used measurable (minimal) residual disease (MRD) to demonstrate the superior outcomes using fixed duration venetoclax in combination with rituximab compared with an older chemoimmunotherapy, bendamustine plus rituximab for the treatment of CLL / SLL.
At the 2021 American Society of Hematology (ASH) annual meeting, Dr. Arnon Kater discussed the evolving results of the Murano trial four years later.
Read the full article on CLL Society's website at: [ Ссылка ]
__________________________________________________________________________________________
CLL Society Website: [ Ссылка ]
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
